Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course;Wpływ stȩzen żelatynaz oraz ich tkankowych inhibitorów w guzie zapalnym i nowotworowym trzustki na wczesne wyniki leczenia resekcyjnego tych chorób

Polski Przeglad Chirurgiczny/ Polish Journal of Surgery

Volumn 85, Issue 2, 2013, Pages 118-130

  Lekstan, Andrzej ^a   Olakowski, Marek ^a   Jablońska, Beata ^a   Łabuzek, Krzysztof ^a   Olakowska, Edyta ^a   Filip, Ines ^a   Lampe, Paweł ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Chronic pancreatitis; Gelatinases; Metalloproteinases; Pancreatic cancer; Tissue inhibitors of metalloproteinases

Indexed keywords

EID: 84880289772     PISSN: 0032373X     EISSN: None     Source Type: Journal    
DOI: 10.2478/pjs-2013-0012     Document Type: Article

References (27)

1. Herszényi L, Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-58.
2. Spanier BW, Dijkgraaf MG, Bruno MJ: Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. Best Pract Res Clin Gastroenterol 2008; 22: 45-63.
3. Łukaszewicz M, Mroczko B. Szmitkowski M: Rola metaloproteinaz i ich inhibitorów w raku trzustki. Postepy Hig Med Dosw 2008; 62: 141-47.
4. Gress TM, Muller-Pillasch F, Lerch MM et al.: Expression and in situ localization of genes encoding for extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13.
5. Bloomston M, Zervos ED, Rosemurgy ASH: Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials. Ann Surg Oncol 2002; 9: 668-74. (Pubitemid 34857984)
6. Maisonneuve P, Lowenfels AB: Epidemiology of pancreatic cancer: an update. Dig Dis 2010; 28: 645-56.
7. Krejs GJ: Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355-58.
8. Pezzilli R: Etiology of chronic pancreatitis: has it changed in the last decade? World J Gastroenterol 2009; 15: 4737-40.
9. Otsuki M: Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol 2003; 38: 315-26. (Pubitemid 36626266)
10. EyigorC, Karaca B, Kuzeyli-Yildirim Y et al.: Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain? J BUON 2010; 15: 543-46.
11. Eshuis WJ, van der Gaag NA, Rauws EA et al.: Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg 2010; 252: 840-49.
12. Braganza JM, Lee SH, McCloy RF et al.: Chronic pancreatitis. Lancet 2011; 377: 1184-97.
13. Kimura W: Strategies for the treatment of invasive ductal carcinoma of the pancreas and how to achieve zero mortality for pancreaticoduodenectomy. J HepatobiliaryPancreat Surg 2008; 15: 270-77. (Pubitemid 351818766)
14. Müller MW, Friess H, Kleeff J et al.: Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions. Ann Surg 2006; 24: 909-18. (Pubitemid 44808624)
15. Hildebrand P, Dudertadt S, Czymek R et al.: Different surgical strategies for chronic pancreatitis significantly improve long-term outcome: a comparative single center study. Eur J Med Res 2010; 15: 351-56.
16. King JC, Abeywardina S, Farrell JJ et al.: A modern review of the operative management of chronic pancreatitis. Am Surg 2010; 76: 1071-74.
17. Frey CF, Amikura K: Local resection of the head of the pancreas combined with longitudinal pan-creaticojejunostomy in the management of patients with chronic pancreatitis. Ann Surg 1994; 220: 92.
18. Brown KM, Tompkins AJ, Yong S et al.: Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140: 529-32.
19. Cameron JL, Ria JL, TS, Coleman J et al.: One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15. (Pubitemid 44297442)
20. Behrman SW, Rush BT, Dilawari RA: A modern analysis of morbidity after pancreatic resection. Am Surg 2004; 70: 675-82.
21. Winter JM, Cameron JL, Campbell KA et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-10.
22. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J et al.: Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma 2003; 50: 383-87. (Pubitemid 37345681)
23. Koshiba T, Hosotani R, Wada M et al.: Detection of matrix m etalloproteinase activity in human pancreatic cancer. Surg Today 1997; 27: 302-04. (Pubitemid 27164188)
24. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U et al.: Clinical significance of the measurements of serum matrix metallopro-teinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38: 613-18.
25. Ellenrieder V, Alber B, Lacher U et al.: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85: 14-20.
26. Yokoyama M, Ochi K, Ichimura M et al.: Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 2002; 24: 344-47. (Pubitemid 34441914)
27. Stumpf M, Klinge U, Wilms A et al.: Changes of the extracellular matrix as a risk factor for anastomotic leakage after large bowel surgery. Surgery 2005; 137: 229-34. (Pubitemid 40174433)